Connect with us

Technology

The Calida Group Announces Promotion of Joshua Nelson to President, Advancing Next Phase of National Growth

Published

on

Nelson’s promotion reflects more than a decade of leadership and comes as The Calida Group expands its national platform, enters new high-growth markets and pursues approximately $1 billion in investments across development, acquisitions, and operations in 2026.

LAS VEGAS, June 24, 2026 /PRNewswire/ — The Calida Group, a vertically integrated multifamily investment, development and operating company, today announced the promotion of Joshua Nelson to president.

In his new role, Nelson will oversee the firm’s day-to-day operations, investment strategy and execution across all business lines while continuing to serve on the company’s Executive Committee and Investment Committee. He will work alongside Co-Founders Douglas Eisner and Eric Cohen to guide Calida’s continued expansion and long-term strategic growth.

Nelson’s promotion comes at a pivotal time for The Calida Group as the company continues to scale its national platform and expects to deploy approximately $1 billion of capital in 2026 across development, acquisitions and operations. Under Nelson’s leadership, Calida has expanded beyond its historic Western U.S. footprint into Texas, Florida, Georgia and other high-growth markets throughout the Southeast, significantly increasing the firm’s geographic reach and investment pipeline.

“Josh has been instrumental in helping build Calida into one of the most active multifamily investment and development platforms in the country,” said Douglas Eisner, co-founder and co-CEO of The Calida Group. “His leadership, and ability to execute across acquisitions, development and operations have helped drive our expansion into new markets and positioned us for sustained growth. Josh has earned the trust of our team, our partners and our investors. We are excited to see him lead Calida into its next chapter.”

Nelson joined Calida after serving on the corporate development and mergers and acquisitions team at Liberty Media and Liberty Interactive, a Fortune 300 investment company. Prior to joining the firm, he was responsible for identifying strategic investment opportunities and leading due diligence efforts across technology, media, telecommunications and renewable energy sectors.

As Chief Investment Officer, Nelson oversaw the firm’s acquisitions, development and asset management activities while helping establish one of the industry’s most active multifamily investment platforms. Under his leadership, Calida expanded beyond its Western U.S. roots by establishing offices in Dallas and Florida, entering new high-growth markets across the Southeast and Texas, growing its development pipeline and strengthening its vertically integrated operating platform.

“Josh has been a key pillar of Calida’s growth strategy for more than a decade,” said Eric Cohen, co-founder and co-CEO of The Calida Group. “He has consistently demonstrated the ability to identify opportunities, build exceptional teams and execute at the highest level. As we continue to expand our platform and deploy significant capital across the country, Josh’s leadership will be critical to our success. This promotion reflects both his contributions to date and our confidence in his ability to help lead the firm for many years to come.”

The promotion also reflects the continued evolution of Calida’s leadership structure as the firm expands its national presence and institutional capabilities. In his role as President, Nelson will assume broader responsibility for coordinating the company’s investment, development, operational and strategic initiatives, allowing the firm’s leadership team to further enhance its focus on long-term growth, investor relationships and new market expansion.

About The Calida Group

The Calida Group is a leading developer, investor, and operator of multifamily real estate properties in the western United States. Founded in 2007 by Douglas Eisner and Eric Cohen, the principals have developed or acquired more than 30,000 multifamily units, and its senior management combines over 100 years of real estate experience. The Calida Group invests roughly $1 billion annually across three primary strategies (Development, Value-Add Acquisitions and Core-Plus Acquisitions) on behalf of a series of discretionary commingled funds serving the family office and ultra-high net worth communities, as well as forming partnerships with many of the nation’s largest financial institutions.

The Calida Group begins with strategic and creative deal sourcing methods to identify investment opportunities that are often completely off market or otherwise less competitively advertised. Then, by leveraging the firm’s lifestyle-oriented design capabilities and operational expertise, The Calida Group tailors unique business plans for each asset. Finally, by meticulously implementing these business plans while managing construction risk, conservatively financing each property and employing thoughtful tax planning, Calida is able to create superior investment opportunities with lower risk than would typically be expected in deals of similar return profiles.

For more information, please visit us at TheCalidaGroup.com, or contact Investor Relations at InvestorRelations@TheCalidaGroup.com

Contact:
Eileen Lopez
***@thecalidagroup.com

Photo(s):
https://www.prlog.org/13154079

Press release distributed by PRLog

View original content:https://www.prnewswire.com/news-releases/the-calida-group-announces-promotion-of-joshua-nelson-to-president-advancing-next-phase-of-national-growth-302809343.html

SOURCE The Calida Group

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

AI in Healthcare Market to Reach USD 505.6 Billion by 2033, Driven by Rapid Adoption of AI-Powered Clinical Solutions and Digital Healthcare Transformation

Published

on

By

Global AI in Healthcare Market Expected to Expand at 38.90% CAGR from 2026 to 2033 as Healthcare Systems Embrace Predictive Analytics, Precision Medicine, and Automation

SAN FRANCISCO, June 24, 2026 /PRNewswire/ — The global artificial intelligence (AI) in healthcare market is projected to witness significant growth, reaching USD 505.59 billion by 2033, according to a new report by Grand View Research, Inc. The market was estimated at USD 36.7 billion in 2025 and is anticipated to grow from USD 50.7 billion in 2026 to USD 505.6 billion by 2033, expanding at a compound annual growth rate (CAGR) of 38.90% during the forecast period from 2026 to 2033.

The increasing demand for advanced healthcare technologies, rising adoption of artificial intelligence-driven clinical decision support systems, growing healthcare data volumes, and the need for improved patient outcomes are accelerating the integration of AI across healthcare ecosystems. AI technologies are enabling healthcare providers to transition from traditional reactive models toward predictive, personalized, and preventive healthcare approaches.

AI Transforming Healthcare Delivery Through Advanced Analytics and Automation

Artificial intelligence is emerging as a transformative technology within the healthcare industry by enabling faster diagnosis, improved treatment planning, operational efficiency, and enhanced patient engagement. AI-powered solutions are being increasingly deployed across medical imaging, clinical decision support, drug discovery, patient monitoring, administrative automation, and personalized medicine applications.

Healthcare organizations are leveraging machine learning, natural language processing, computer vision, and deep learning technologies to analyze complex medical datasets, identify disease patterns, and support healthcare professionals with actionable insights. The ability of AI systems to process large-scale clinical information is helping improve diagnostic accuracy and optimize healthcare workflows.

Clinical decision support systems powered by AI are becoming increasingly important as healthcare providers seek real-time insights to enhance decision-making and improve patient care outcomes. These solutions assist physicians by analyzing patient information, identifying potential risks, and supporting evidence-based treatment strategies.

Get Free Sample of this Research Report for more latest industry insights

Rising Healthcare Data Volumes and Digital Transformation Fuel Market Growth

The rapid digitization of healthcare infrastructure is one of the major factors contributing to the expansion of the AI in healthcare market. The increasing adoption of electronic health records (EHRs), connected medical devices, wearable technologies, and remote patient monitoring solutions is generating substantial amounts of healthcare data.

AI platforms are helping organizations convert this data into meaningful clinical and operational intelligence. Healthcare providers are increasingly adopting AI solutions to improve resource utilization, streamline workflows, reduce operational costs, and deliver more personalized patient experiences.

The growing prevalence of chronic diseases, increasing healthcare expenditure, and rising demand for efficient healthcare delivery models are further supporting market growth. AI-driven solutions are enabling healthcare systems to improve early disease detection, enhance treatment outcomes, and support continuous patient monitoring.

Software Segment and AI-Based Solutions Drive Healthcare Innovation

The AI in healthcare market is segmented by component, application, technology, end use, and region. The market includes hardware, software, and services components, with AI software solutions playing a critical role in enabling advanced analytics, automation, and decision-support capabilities.

AI applications across clinical trials, cybersecurity, medical imaging analysis, robotic-assisted procedures, drug discovery, and healthcare management are expanding rapidly as organizations invest in intelligent healthcare infrastructure.

The integration of AI into clinical research is also creating new opportunities by improving patient recruitment, accelerating data analysis, and supporting faster development of medical innovations. AI technologies are helping pharmaceutical and biotechnology companies analyze complex biological data and enhance research efficiency.

Growing Adoption of AI in Precision Medicine and Personalized Healthcare

The increasing focus on personalized medicine is creating new growth opportunities for AI adoption in healthcare. AI algorithms can analyze patient-specific information, including medical history, genetic data, and clinical indicators, to support individualized treatment strategies.

Precision healthcare initiatives are increasingly using AI to identify disease risks, predict treatment responses, and improve therapeutic outcomes. The technology is supporting advancements in areas such as oncology, cardiology, neurology, and diagnostics by enabling more accurate and timely medical interventions.

AI-powered healthcare platforms are also contributing to remote care models by supporting virtual healthcare services, remote monitoring, and patient engagement solutions. These capabilities are becoming increasingly important as healthcare systems worldwide focus on improving accessibility and efficiency.

North America Leads AI Healthcare Adoption While Asia Pacific Presents Growth Opportunities

North America continues to represent a significant region for AI healthcare adoption due to advanced healthcare infrastructure, strong technology investments, and increasing implementation of digital health solutions. The region benefits from the presence of leading technology companies, healthcare organizations, and research institutions focused on AI innovation.

Meanwhile, Asia Pacific is expected to witness strong growth opportunities due to increasing healthcare digitalization, rising investments in healthcare technology, improving healthcare infrastructure, and growing demand for advanced medical solutions.

Countries across emerging markets are increasingly exploring AI applications to improve healthcare accessibility, address workforce challenges, and enhance diagnostic capabilities.

Browse more Research Reports in Healthcare IT Industry

Competitive Landscape and Industry Outlook

The global AI in healthcare market includes several prominent technology and healthcare companies focusing on innovation, strategic partnerships, and development of advanced AI platforms. Key companies profiled in the market include Microsoft, IBM, NVIDIA Corporation, Intel Corporation, GE Healthcare, Google, Medtronic, Oracle, Medidata, Merck, and IQVIA.

Market participants are investing in research and development activities, AI-enabled healthcare platforms, cloud-based solutions, and strategic collaborations to strengthen their market position.

As healthcare organizations continue adopting artificial intelligence technologies, AI is expected to play a central role in improving clinical decision-making, operational efficiency, and patient outcomes globally.

Grand View Research Report Coverage

The Grand View Research report provides an in-depth analysis of the artificial intelligence in healthcare market, including market size, growth trends, competitive landscape, segment analysis, and regional insights. The report covers historical data from 2021 to 2025 and provides forecasts for the period from 2026 to 2033.

To learn more about growth opportunities in the AI In Healthcare Market, access the full report from Grand View Research

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research Helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

Browse GVR’s U.S. Healthcare Facility Mapping & Intelligence Platform

Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
Web: https://www.grandviewresearch.com
Follow Us: LinkedIn | Twitter
Blog – https://globalindustryherald.com/

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/ai-in-healthcare-market-to-reach-usd-505-6-billion-by-2033–driven-by-rapid-adoption-of-ai-powered-clinical-solutions-and-digital-healthcare-transformation-302808113.html

Continue Reading

Technology

Club Offers for Travel Enthusiasts in the U.S.

Published

on

By

NEW YORK, June 24, 2026 /PRNewswire/ — Travelzoo® (NASDAQ: TZOO), the club for travel enthusiasts, announces a new Club Offer for Club Members in the U.S.

Rigorously vetted and negotiated for us travel enthusiasts:

$899—NEW MEXICO ALL-INCLUSIVE VACATION WITH FLIGHTS
This Riviera Maya resort has been completely transformed. In September, it will debut as a luxurious Kimpton resort. Everything has been refreshed, from the suites to the restaurants and public spaces. This package includes roundtrip flights, 5 nights’ accommodations, airport transfers and all meals and drinks. You can also add additional nights for longer stays. It’s rare to find opening-season rates this low at a brand-new luxury resort, especially when rooms here sell for $400-$600 per night. We’ve negotiated this Club Offer just for us.

Are you a travel enthusiast? Join the club today: https://travelzoo.com

Who are we?
We, Travelzoo®, are the club for travel enthusiasts. We reach 30 million travelers. Club Members receive Club Offers negotiated and rigorously vetted by our deal experts around the globe. Our relationships with thousands of top travel companies give us access to irresistible deals. Our club and its benefits are built around the lifestyle of a modern travel enthusiast.

Media Contact: 

Jonathan Jones – New York
jjones@travelzoo.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/club-offers-for-travel-enthusiasts-in-the-us-302809648.html

SOURCE Travelzoo

Continue Reading

Technology

Royce Micro-Cap Trust (NYSE: RMT) as of May 31, 2026

Published

on

By

NEW YORK, June 24, 2026 /PRNewswire/ — 

Average weekly trading volume of approximately 531,385 sharesFund’s adviser has more than 50 years of small- and micro-cap investment experience

CLOSING PRICES AS OF 05/31/26

NAV

15.73

MKT

14.04

AVERAGE ANNUAL TOTAL RETURN AS OF 05/31/26

NAV (%)

MKT (%)

One-Month*

6.21

6.20

Year to Date*

35.72

36.93

One-Year

70.80

73.35

Three-Year

28.50

29.82

Five-Year

11.90

11.99

10-Year

15.25

15.81

*Not Annualized

Important Performance and Expense Information

All performance information reflects past performance, is presented on a total return basis, net of the Fund’s investment advisory fee, and reflects the reinvestment of distributions. Past performance is no guarantee of future results Current performance may be higher or lower than performance quoted. Returns as of the recent month-end may be obtained at www.royceinvest.com. The market price of the Fund’s shares will fluctuate, so that shares may be worth more or less than their original cost when sold.

The Fund normally invests in micro-cap companies, which may involve considerably more risk than investing in larger-cap companies. The Fund’s broadly diversified portfolio does not ensure a profit or guarantee against loss.

PORTFOLIO DIAGNOSTICS

Average Market Cap1

$1070.9M

Weighted Average P/B2

2.3x

Net Assets

$847.4M

Net Leverage

1.5 %

1Geometric Average: This weighted calculation uses each portfolio holding’s market cap in a way designed to not skew the effect of very large or small holdings; instead, it aims to better identify the portfolio’s center, which Royce believes offers a more accurate measure of average market cap than a simple mean or median.

2Harmonic Average: This weighted calculation evaluates a portfolio as if it were a single stock and measures it overall. It compares the total market value of the portfolio to the portfolio’s share in the earnings of its underlying stocks.

The Price-to-Book, or P/B, Ratio is calculated by dividing a company’s share price by its book value per share.

Net leverage is the percentage, in excess of 100 %, of the total value of equity type investments, divided by net assets.

Portfolio Composition

TOP 10 POSITIONS

% OF NET ASSETS (SUBJECT TO CHANGE)

5N Plus

1.8

Cohu

1.5

Ichor Holdings

1.5

NWPX Infrastructure

1.4

Ultra Clean Holdings

1.4

ADTRAN Holdings

1.4

EZCORP Cl. A

1.3

Vishay Precision Group

1.3

Bel Fuse Cl. B

1.3

Graham Corporation

1.3

TOP FIVE SECTORS

% OF NET ASSETS (SUBJECT TO CHANGE)

Industrials

28.4

Information Technology

25.0

Financials

12.8

Health Care

11.9

Consumer Discretionary

10.8

Recent Developments
Royce Micro-Cap Trust, Inc. is a closed-end diversified investment company whose shares of Common Stock (RMT) are listed and traded on the New York Stock Exchange. The Fund’s investment goal is long-term capital growth, which it seeks by investing primarily in equity securities of companies that, at the time of investment, have market capitalization of $1 billion or less.

Daily net asset values (NAVs) for Royce Micro-Cap Trust, Inc. are now available on our website and online through most ticker symbol lookup services and on broker terminals under the symbol XOTCX. For more information, please call The Royce Funds at (800) 221-4268 or visit our website at www.royceinvest.com 

An investor in Royce Micro-Cap Trust should consider the Fund’s investment goals, risks, fees, and expenses carefully before investing.

Important Disclosure Information
Closed-End Funds are registered investment companies whose shares of common stock may trade at a discount to their net asset value. Shares of each Fund’s common stock are also subject to the market risks of investing in the underlying portfolio securities held by the Fund. Royce Fund Services, LLC. (“RFS”) is a member of FINRA and has filed this material with FINRA on behalf of each Fund. RFS does not serve as a distributor or as an underwriter to the closed-end funds.

View original content:https://www.prnewswire.com/news-releases/royce-micro-cap-trust-nyse-rmt-as-of-may-31-2026-302809653.html

SOURCE Royce Micro-Cap Trust, Inc.

Continue Reading

Trending